Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1989 1
2004 1
2005 1
2006 2
2008 3
2010 1
2011 2
2012 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Role of exercise and nutrition in menopause.
Hagey AR, Warren MP. Hagey AR, et al. Clin Obstet Gynecol. 2008 Sep;51(3):627-41. doi: 10.1097/GRF.0b013e318180ba84. Clin Obstet Gynecol. 2008. PMID: 18677156 Review.
Increasing diversity in pediatric hematology/oncology.
Frugé E, Lakoski JM, Luban N, Lipton JM, Poplack DG, Hagey A, Felgenhauer J, Hilden J, Margolin J, Vaiselbuh SR, Sakamoto KM. Frugé E, et al. Among authors: hagey a. Pediatr Blood Cancer. 2011 Jul 15;57(1):147-52. doi: 10.1002/pbc.22977. Epub 2011 Jan 31. Pediatr Blood Cancer. 2011. PMID: 21284078 Free PMC article.
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Yee KW, et al. Among authors: hagey a. Clin Cancer Res. 2005 Sep 15;11(18):6615-24. doi: 10.1158/1078-0432.CCR-05-0650. Clin Cancer Res. 2005. PMID: 16166440 Free article. Clinical Trial.
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. Fox E, et al. Among authors: hagey ae. Clin Cancer Res. 2008 Feb 15;14(4):1111-5. doi: 10.1158/1078-0432.CCR-07-4097. Clin Cancer Res. 2008. PMID: 18281544 Free article. Clinical Trial.
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. Fox E, et al. Among authors: hagey ae. Clin Cancer Res. 2006 Aug 15;12(16):4882-7. doi: 10.1158/1078-0432.CCR-06-0534. Clin Cancer Res. 2006. PMID: 16914576 Free article. Clinical Trial.
13 results